These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 33777033)

  • 21. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer.
    Cifaldi L; Di Santo J; Olive D
    Front Immunol; 2020; 11():1132. PubMed ID: 32612604
    [No Abstract]   [Full Text] [Related]  

  • 22. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
    Ben-Shmuel A; Biber G; Barda-Saad M
    Front Immunol; 2020; 11():275. PubMed ID: 32153582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exercise Benefits Meet Cancer Immunosurveillance: Implications for Immunotherapy.
    Fiuza-Luces C; Valenzuela PL; Castillo-García A; Lucia A
    Trends Cancer; 2021 Feb; 7(2):91-93. PubMed ID: 33358110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Control of Metastasis by NK Cells.
    López-Soto A; Gonzalez S; Smyth MJ; Galluzzi L
    Cancer Cell; 2017 Aug; 32(2):135-154. PubMed ID: 28810142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of tumor cells escaping from immune surveillance of NK cells.
    Ge Z; Wu S; Zhang Z; Ding S
    Immunopharmacol Immunotoxicol; 2020 Jun; 42(3):187-198. PubMed ID: 32223464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Natural Killer Cells for Tumor Immunotherapy.
    Zhang C; Hu Y; Shi C
    Front Immunol; 2020; 11():60. PubMed ID: 32140153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NK cells in the tumor microenvironment: Prognostic and theranostic impact. Recent advances and trends.
    Russick J; Torset C; Hemery E; Cremer I
    Semin Immunol; 2020 Apr; 48():101407. PubMed ID: 32900565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors.
    Kim N; Lee DH; Choi WS; Yi E; Kim H; Kim JM; Jin HS; Kim HS
    BMB Rep; 2021 Jan; 54(1):44-58. PubMed ID: 33298244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural killer cells: a review of biology, therapeutic potential and challenges in treatment of solid tumors.
    Choucair K; Duff JR; Cassidy CS; Albrethsen MT; Kelso JD; Lenhard A; Staats H; Patel R; Brunicardi FC; Dworkin L; Nemunaitis J
    Future Oncol; 2019 Sep; 15(26):3053-3069. PubMed ID: 31411057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma.
    Chiu J; Ernst DM; Keating A
    Front Immunol; 2018; 9():267. PubMed ID: 29491867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelets, Thrombo-Inflammation, and Cancer: Collaborating With the Enemy.
    Palacios-Acedo AL; Mège D; Crescence L; Dignat-George F; Dubois C; Panicot-Dubois L
    Front Immunol; 2019; 10():1805. PubMed ID: 31417569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Antitumor Cytotoxic Response: If the Killer Cells Play the Music, the Microenvironmental Hypoxia Plays the Tune.
    Chouaib S
    Crit Rev Immunol; 2020; 40(2):157-166. PubMed ID: 32749093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT.
    Tumino N; Di Pace AL; Besi F; Quatrini L; Vacca P; Moretta L
    Front Immunol; 2021; 12():638841. PubMed ID: 33679798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural killer cells in cancer biology and therapy.
    Wu SY; Fu T; Jiang YZ; Shao ZM
    Mol Cancer; 2020 Aug; 19(1):120. PubMed ID: 32762681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lysis of tumor cells by natural killer cells in mice is impeded by platelets.
    Nieswandt B; Hafner M; Echtenacher B; Männel DN
    Cancer Res; 1999 Mar; 59(6):1295-300. PubMed ID: 10096562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of natural killer cell anti-tumor reactivity by platelets.
    Placke T; Kopp HG; Salih HR
    J Innate Immun; 2011; 3(4):374-82. PubMed ID: 21411974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NK Cell Metabolism and Tumor Microenvironment.
    Terrén I; Orrantia A; Vitallé J; Zenarruzabeitia O; Borrego F
    Front Immunol; 2019; 10():2278. PubMed ID: 31616440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic adaptations determine whether natural killer cells fail or thrive within the tumor microenvironment.
    Moinuddin A; Poznanski SM; Portillo AL; Monteiro JK; Ashkar AA
    Immunol Rev; 2024 May; 323(1):19-39. PubMed ID: 38459782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.